NCT03735121CompletedPhase 3
A Randomized, Multicenter, Phase Ib/III Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous Compared With Atezolizumab Intravenous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Hoffmann-La Roche74 sites in 17 countries438 target enrollmentStarted: December 27, 2018Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 438
- Locations
- 74
- Primary Endpoint
- Part 1: Serum Trough Concentration (Ctrough) of Atezolizumab at Cycle 1
Study Overview
Brief Summary
This study will evaluate the pharmacokinetics, safety, and efficacy of atezolizumab subcutaneous (SC) compared with atezolizumab intravenous (IV) in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) who have not been exposed to cancer immunotherapy (CIT) and for whom prior platinum-based therapy has failed. The study is comprised of two parts, as follows: A dose-finding part (Part 1, Phase Ib) will aim to identify the dose of atezolizumab SC to be tested in Part 2. A dose-confirmation part (Part 2, Phase III, randomized) will aim to confirm that the dose moved forward from Part 1 yields drug exposure that is comparable to that of atezolizumab IV.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically or cytologically documented locally advanced or metastatic NSCLC
- •Prior platinum-containing regimen or disease recurrence ≤ 6 months since prior platinum-based adjuvant/neoadjuvant regimen.
- •Measurable disease as defined by RECIST v1.1
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- •Life expectancy ≥12 weeks
- •Adequate hematologic and end-organ function
- •Additional Inclusion Criteria (Part 2 Only) • Availability of tissue and known epidermal growth factor receptor (EGFR) status
Exclusion Criteria
- •Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
- •Uncontrolled or symptomatic hypercalcemia
- •Pregnancy or breastfeeding
- •Active or history of autoimmune disease or immune deficiency
- •History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
- •Severe infection ≤ 4 weeks
- •Treatment with therapeutic oral or IV antibiotics ≤ 2 weeks prior to study treatment
- •Significant cardiovascular disease
- •Prior allogeneic stem cell or solid organ transplantation
- •Treatment with a live, attenuated vaccine ≤ 4 weeks
- •Treatment with systemic immunostimulatory agents ≤ 4 weeks or 5 half-lives of the drug
- •Treatment with systemic immunosuppressive medication ≤ 2 weeks
- •Additional Exclusion Criteria (Part 2 Only)
- •Tested tumor programmed death-ligand-1 (PD-L1) expression status with an intention to treat the patient if positive
Arms & Interventions
Atezolizumab (Part 2)
Experimental
Atezolizumab
Intervention: Atezolizumab (Drug)
Cohort 1: Atezolizumab+rHuPH20 (Part 1)
Experimental
Atezolizumab+recombinant human hyaluronidase (rHuPH20), followed by Atezolizumab
Intervention: Atezolizumab (Drug)
Cohort 1: Atezolizumab+rHuPH20 (Part 1)
Experimental
Atezolizumab+recombinant human hyaluronidase (rHuPH20), followed by Atezolizumab
Intervention: rHuPH20 (Drug)
Cohort 2: Atezolizumab+rHuPH20 (Part 1)
Experimental
Atezolizumab+rHuPH20, followed by Atezolizumab
Intervention: Atezolizumab (Drug)
Cohort 2: Atezolizumab+rHuPH20 (Part 1)
Experimental
Atezolizumab+rHuPH20, followed by Atezolizumab
Intervention: rHuPH20 (Drug)
Cohort 3: Atezolizumab+rHuPH20(Part 1)
Experimental
Atezolizumab+rHuPH20, followed by Atezolizumab
Intervention: Atezolizumab (Drug)
Cohort 3: Atezolizumab+rHuPH20(Part 1)
Experimental
Atezolizumab+rHuPH20, followed by Atezolizumab
Intervention: rHuPH20 (Drug)
Atezolizumab + rHuPH20 (Part 2)
Experimental
Atezolizumab + rHuPH20
Intervention: Atezolizumab (Drug)
Atezolizumab + rHuPH20 (Part 2)
Experimental
Atezolizumab + rHuPH20
Intervention: rHuPH20 (Drug)
Outcomes
Primary Outcomes
Part 1: Serum Trough Concentration (Ctrough) of Atezolizumab at Cycle 1
Time Frame: Pre-dose on Day 1 of Cycle 2 (Cycle length=21 days for cohorts 1 and 3 and 14 days for cohort 2)
Part 2: Observed Serum Ctrough of Atezolizumab at Cycle 1
Time Frame: Predose on Day 1 of Cycle 2 (Cycle length =21 days)
Part 2: Area Under the Concentration-Time Curve From Time Zero to 21 Days (AUC 0-21 d) at Cycle 1
Time Frame: From start of dosing up to Day 21 in Cycle 1 (Cycle length = 21 days)
Secondary Outcomes
- Part 1: Maximum Observed Serum Concentration (Cmax) of Atezolizumab(Predose and post dose on Day 1 of Cycle 1 and post dose on Days 3 and 8 of Cycle 1 (Cycle length = 21 days for cohorts 1 and 3 and 14 days for cohort 2))
- Part 1: Time to Maximum Serum Concentration (Tmax) of Atezolizumab(Predose and post dose on Day 1 of Cycle 1 and post dose on Days 3 and 8 of Cycle 1 (Cycle length = 21 days for cohorts 1 and 3 and 14 days for cohort 2))
- Part 1: Area Under the Concentration-time Curve (AUClast) of Atezolizumab(Predose and up to 21 days post dose in Cycle 1 for cohorts 1 and 3 and from predose up to 14 days post last dose in Cycle 1 for cohort 2 (Cycle length= 21 days for cohorts 1 and 3 and 14 days for cohort 2))
- Part 1: Serum Atezolizumab Concentration at Specified Timepoint During SC Administration(Cohort 1: Predose: D1 & postdose: D1, 3, 8 of C1; Cohort 2: Pre & postdose: D1 of C1, 3 & postdose: D3, 8 of C1, Predose: D1 of C2; Cohort 3: Pre & postdose: D1 of C1, 2 & postdose: D3, 8 of C1, D2, 4 & 9 of C2 & pre dose: D1 of C3)
- Part 1: Percentage of Participants With Adverse Events (AEs)(From initiation of study treatment up to approximately 69 months)
- Part 2: Percentage of Participants With AEs(From initiation of study treatment up to approximately 44.7 months)
- Part 2: Model Predicted Ctrough of Atezolizumab at Cycle 1(Cycle 1 (Cycle length=21 days))
- Part 2: Model Predicted Ctrough at Steady State (Ctrough,ss) of Atezolizumab(Atezo SC: Pre&postdose C1D1, postdose C1 Days 2,4,8, Pre&postdose C2,D1 and Predose on D1 of C3,4,8,12 and 16 ; Atezo IV: Pre&postdose on C1D1, postdose C1 Days 2,4,8; Pre&postdose C2D1, Predose on D1 of C3,4,8,12, and 16 (up to approximately 16 months))
- Part 2: Model Predicted AUC at Steady State (AUCss) of Atezolizumab(Atezo SC: Pre&postdose C1D1, postdose C1 Days 2,4,8, Pre&postdose C2,D1 and Predose on D1 of C3,4,8,12 and 16 ; Atezo IV: Pre&postdose on C1D1, postdose C1 Days 2,4,8; Pre&postdose C2D1, Predose on D1 of C3,4,8,12, and 16 (up to approximately 16 months))
- Part 2: Objective Response Rate (ORR)(Up to approximately 25 months)
- Part 2: Progression-free Survival (PFS)(Up to approximately 25 months)
- Part 2: Overall Survival (OS)(Up to approximately 44.7 months)
- Part 2: Duration of Response (DOR)(Up to approximately 25 months)
- Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score(Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 (Cycle length = 21 days), and Treatment Discontinuation Visit (up to approximately 44 months))
- Part 2: Change From Baseline in EORTC IL57 Role Functioning Score(Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 (Cycle length = 21 days), and Treatment Discontinuation Visit (up to approximately 44 months))
- Part 2: Change From Baseline in EORTC IL57 Global Health Status Score(Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 (Cycle length = 21 days), and Treatment Discontinuation Visit (up to approximately 44 months))
- Part 2: Overall Satisfaction With Treatment Over Time, Assessed by the Modified Satisfaction With Therapy (SWT) Scale of the Cancer Therapy Satisfaction Questionnaire (CTSQ)(Day 1 Cycle 3 or Treatment Discontinuation Visit (if treatment discontinued at any visit before Cycle 3) (Cycle length = 21 days))
- Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57(Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, and 64 (Cycle length = 21 days))
- Part 2: Percentage of Participants With Ant-Drug Antibodies (ADAs) to Atezolizumab After SC or IV Administration(From Cycle 1 Day 1 (Cycle length = 21 days) up to treatment discontinuation visit (Up to approximately 20 months))
- Part 2: Percentage of Participants With ADAs to rHuPH20 After SC Administration(From Cycle 1 Day 1 (Cycle length = 21 days) up to treatment discontinuation visit (Up to approximately 20 months))
- Part 2: Percentage of Health Care Professionals (HCPs) by Their Response to Question 2 of HCP SC Versus IV Perspective Questionnaire(After HCP has completed administering at least 3 doses of atezolizumab SC and IV across all participants in Part 2 (Up to approximately 48 months))
- Part 2: Percentage of HCPs by Their Response to Question 3 of the HCP SC Versus IV Perspective Questionnaire(After HCP has completed administering at least 3 doses of atezolizumab SC and IV across all participants in Part 2 (Up to approximately 48 months))
- Part 2: Percentage of HCPs by Their Response to Question 4 of the HCP SC Versus IV Perspective Questionnaire(After HCP has completed administering at least 3 doses of atezolizumab SC and IV across all participants in Part 2 (Up to approximately 48 months))
- Part 2: Percentage of HCPs by Their Response to Question 2 of the HCP SC Perspective Questionnaire(After HCP has completed administering at least 3 doses of atezolizumab SC across all participants in Part 2 (Up to approximately 48 months))
- Part 2: Percentage of HCPs by Their Response to Question 3 of the HCP SC Perspective Questionnaire(After HCP has completed administering at least 3 doses of atezolizumab SC across all participants in Part 2 (Up to approximately 48 months))
- Part 2: Percentage of HCPs by Their Response to Question 4 of the HCP SC Perspective Questionnaire(After HCP has completed administering at least 3 doses of atezolizumab SC across all participants in Part 2 (Up to approximately 48 months))
Investigators
Study Sites (74)
Loading locations...
Similar Trials
Terminated
Phase 3
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast CancerTriple Negative Breast CancerNCT03498716Hoffmann-La Roche2,199
Completed
Phase 2
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell CarcinomaRenal Cell CarcinomaNCT01984242Hoffmann-La Roche305
Terminated
Phase 1
A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT03922477Hoffmann-La Roche13
Terminated
Phase 3
A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and NeckLocally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)NCT03452137Hoffmann-La Roche406
Completed
Phase 1
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid TumorsSolid TumorNCT02715531Hoffmann-La Roche243
Related News
FDA Approves Subcutaneous Tecentriq Hybreza for Multiple Cancer Types- The FDA has approved Tecentriq Hybreza, a subcutaneous formulation of atezolizumab, for various cancer indications, offering a new administration route.
- Approval was based on the IMscin001 trial, which demonstrated comparable atezolizumab exposure between subcutaneous and intravenous administrations.
- Tecentriq Hybreza combines atezolizumab with hyaluronidase to enhance subcutaneous tissue permeability, facilitating drug delivery.
- The new formulation provides a faster, approximately 7-minute subcutaneous injection option compared to intravenous infusions.2 years agoFDA Approves Subcutaneous Atezolizumab (Tecentriq Hybreza) for Multiple Cancer Types- The FDA has approved a subcutaneous formulation of atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for all indications of intravenous atezolizumab.
- This includes non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part sarcoma.
- The approval was based on the IMscin001 trial, which demonstrated comparable drug levels and similar safety and efficacy profiles to IV administration.
- The subcutaneous injection offers a faster, more convenient administration route, taking approximately 7 minutes compared to 30-60 minutes for IV infusion.2 years ago